Douglas Grayson, MD
Ophthalmology · Iselin, NJNPI 1689674129
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Alcon at 28.6% of the total. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 516 payments — averaging $306.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$45K
- Johnson & Johnson Surgical Vision, Inc.$41K
- Glaukos Corporation$24K
- NEW World Medical,inc.$23K
- AbbVie$19K
- Alcon Research LLC$2K
- plus $5K from 16 others
Across 2 payments — averaging $8500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$17K
What the payments were for
- Consulting fees$73,73247%
- Speaking & faculty fees$49,96332%
- Travel & lodging$3900%
- Food & beverage$34,09922%
- Education$180%
- Gifts$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 65 | $45,287 |
| Johnson & Johnson Surgical Vision, Inc. | 77 | $40,979 |
| Glaukos Corporation | 43 | $23,669 |
| NEW World Medical,inc. | 42 | $22,801 |
| AbbVie(2 entities) | 199 | $18,570 |
| Alcon Research LLC | 1 | $1,750 |
| Sight Sciences, Inc. | 26 | $1,627 |
| Rxsight Inc | 10 | $788 |
| Bausch & Lomb Americas Inc. | 17 | $784 |
| Harrow Eye, LLC | 6 | $429 |
| Topcon Healthcare, Inc. | 3 | $347 |
| Biotissue Holdings Inc. | 8 | $250 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $192 |
| Sanofi | 2 | $191 |
| Dompe US, Inc. | 4 | $139 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $121 |
| Omeros Corporation | 1 | $118 |
| Ivantis, Inc | 1 | $92 |
| Carl Zeiss Meditec, Inc. | 1 | $51 |
| Ocular Therapeutix, Inc. | 2 | $30 |
| Tarsus Pharmaceuticals, Inc. | 1 | $22 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$54,338
- Clareon$37,303
- XEN GLAUCOMA TREATMENT SYSTEM$15,128
- Ahmed Glaucoma Valve$12,929
- Kahook Dual Blade$12,929
- AcrySof IQ PanOptix UV IOL$12,850
- Streamline Surgical System$7,286
- AcrySof IQ VIVITY$5,000
- iStent Trabecular Micro-Bypass Stent System$4,051
- Clearpath$4,051
- Streamline$4,051
- Tecnis Multifocal Family of 1-piece IOLS$3,105
- Tecnis Symfony IOL$3,000
- Tecnis Simplicity$2,384
- VERITAS Vision System$2,163
- Via360$2,151
- AcrySof IQ VIVITY IOL$1,895
- iStent inject Trabecular Micro-Bypass Stent System$1,347
- OMNI(R) SURGICAL SYSTEM (US)$1,326
- Hydrus Microstent$1,152
How this compares
$158,253 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 353 | $184,050 |
| Prednisolone Acetate | 4,089 | $149,502 |
| MoxifloxacinMoxifloxacin Hcl | 3,674 | $87,594 |
| RestasisCyclosporine | 62 | $70,102 |
| VyzultaLatanoprostene Bunod | 160 | $69,608 |
| XiidraLifitegrast | 47 | $64,244 |
| Alphagan PBrimonidine Tartrate | 102 | $41,736 |
| Timolol Maleate | 1,020 | $38,550 |
| CombiganBrimonidine Tartrate/Timolol | 83 | $28,238 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $24,316 |
| Latanoprost | 2,196 | $21,249 |
| Brimonidine Tartrate | 206 | $19,632 |
| RhopressaNetarsudil Mesylate | 51 | $18,268 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 65 | $17,701 |
| Cyclosporine | 28 | $17,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $18,570 | $324,126600 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $784 | $133,853207 claims |
| AlconSimbrinza, Azopt | $45,287 | $23,76176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Iselin
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Susan HughesCherry Hill$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.